This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21-27 May 2023 and includes updates on COVID-19, influenza, Marburg virus disease, poliomyelitis, extensively drug-resistant Pseudomonas aeruginosa, and suspected fungal meningitis.
This report presents the results of the first external quality assurance (EQA) scheme for B. pertussis antimicrobial susceptibility testing by ECDC as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) consortium.
This report presents the results of the first external quality assessment (EQA) scheme for Bordetella pertussis vaccine antigen expression, pertactin (PRN), pertussis toxin (PT) and filamentous haemagglutinin (FHA) by the European Centre for Disease Prevention and Control (ECDC) as part of the European Reference Laboratory Network for Pertussis (ERLNPert-Net) activities.
Following a peak at week 51/2022, influenza activity had been decreasing across the Region until week 4/2023, before rising again to fluctuate around 25% positivity between weeks 6 and 11/2023 and decreasing below 10% positivity in week 16/2023.